Overview Financials News + Filings IR Vault Key Docs Charts Ownership Insiders
|
|
SCIELE PHARMA, INC. (SCRX)
|
Add to portfolio |
|
|
|
| Price: |
$18.65
| | Metrics |
| OS: |
35.0
|
M
| |
|
|
| Market cap: |
$654
|
M
| |
|
|
|
Net debt:
|
$223
|
M
| |
|
|
|
EV:
|
$877
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-07 | Dec-31-06 | Dec-31-05 | Dec-31-04 | Dec-31-03 | Dec-31-02 | Dec-31-01 | Dec-31-00 |
| Revenues | 382.3 | 293.2 | 216.4 | 152.0 | 95.3 | 115.2 | 69.3 | 36.7 |
| Revenue growth | 30.4% | 35.5% | 42.4% | 59.5% | -17.3% | 66.2% | 89.1% | |
| Cost of goods sold | 52.8 | 40.7 | 33.3 | 29.1 | 17.7 | 24.0 | 10.4 | 5.4 |
| Gross profit | 329.5 | 252.5 | 183.0 | 122.9 | 77.6 | 91.2 | 58.9 | 31.2 |
| Gross margin | 86.2% | 86.1% | 84.6% | 80.9% | 81.4% | 79.2% | 85.1% | 85.2% |
| Selling, general and administrative | 190.8 | 145.3 | 97.4 | 66.8 | 57.8 | 61.8 | 38.7 | 24.2 |
| Research and development | 32.7 | 16.6 | 4.1 | 1.5 | 2.1 | 1.1 | 1.8 | 1.8 |
| EBIT | 77.6 | 64.7 | 58.9 | 37.7 | 1.2 | 13.8 | 15.7 | 4.1 |
| EBIT margin | 20.3% | 22.1% | 27.2% | 24.8% | 1.2% | 12.0% | 22.7% | 11.2% |
| Pre-tax income | 68.2 | 66.4 | 58.4 | 39.0 | -2.8 | 10.1 | 17.6 | 4.2 |
| Income taxes | 22.8 | 21.1 | 19.2 | 12.4 | -1.0 | 3.9 | 6.9 | 1.7 |
| Tax rate | 33.4% | 31.8% | 32.8% | 31.9% | 37.5% | 39.0% | 39.0% | 39.8% |
| Net income | 45.4 | 45.2 | 39.2 | 26.6 | -1.7 | 6.2 | 10.7 | 2.5 |
| Net margin | 11.9% | 15.4% | 18.1% | 17.5% | -1.8% | 5.4% | 15.5% | 6.8% |
| |
| Diluted EPS | $1.25 | $1.18 | $0.92 | $0.63 | ($0.05) | $182.70 | $0.41 | $0.13 |
| Shares outstanding (diluted) | 36.4 | 38.2 | 42.5 | 42.4 | 35.1 | 0.0 | 25.8 | 19.1 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|